THE RIMINOPHENAZINE AGENTS CLOFAZIMINE AND B669 REVERSE ACQUIRED MULTIDRUG-RESISTANCE IN A HUMAN LUNG-CANCER CELL-LINE
THE RIMINOPHENAZINE AGENTS CLOFAZIMINE AND B669 REVERSE ACQUIRED MULTIDRUG-RESISTANCE IN A HUMAN LUNG-CANCER CELL-LINE
复制标题
DOI：
10.1016/0304-3835(94)90239-9
复制
发表时间：
1994-09-30
期刊：
影响因子：
9.7
通讯作者：
OSULLIVAN, JF
中科院分区：
文献类型：
--
作者：
VANRENSBURG, CEJ;ANDERSON, R;OSULLIVAN, JF
The potential of the riminophenazine agents clofazimine and B669, at therapeutically relevant concentrations, to reverse P-glycoprotein-mediated multidrug-resistance (MDR) in a human lung cancer cell line (H69/LX4) has been investigated in vitro. Cyclosporin A, a well-documented MDR-modifying agent, was included for comparison. Clofazimine, B669 and cyclosporin A at minimally cytotoxic concentrations of 1, 0.5 and 5 pg/ml, respectively, were equally effective in restoring sensitivity to vinblastine, doxorubicin, daunorubicin and mitomycin C in the H69/LX4 cell line, All three chemosensitising agents also increased the accumulation of [C-14]vinblastine by H69/LX4 cells. Riminophenazines, which are relatively non-toxic, non-carcinogenic and non-myelosuppressive agents, are promising contenders for evaluation in experimental and clinical oncology as modulators of acquired MDR.
